BOULDER, CO, November 16, 2018 – AmideBio LLC, a privately held biopharmaceutical company, announced today that David Brunel, a board member of AmideBio, has assumed the role of Chairman of the Board, replacing Misha Plam. Dr. Plam, a founder of AmideBio who retired recently as President and CEO, is now Chairman Emeritus.
“I am honored to assume this role from Dr. Plam and look forward to working with Dr. Fludzinski as the Company pursues the development of its drug candidates targeting metabolic disease,” said Mr. Brunel. “On behalf of the Board of Directors, we would like to thank Dr. Plam for his considerable effort in support of the growth of AmideBIo.”
“From all of us at AmideBio, we thank Dr. Plam for his contribution,” said Pawel Fludzinski, CEO and President. “I look forward to working with Mr. Brunel as well as the rest of the Board during this transition period and into the future as we advance our research programs targeting diabetes and other metabolic diseases.”
David Brunel is currently Chief Executive Officer and Director of Biodesix. Mr. Brunel was a co-founder and President of SomaLogic, Inc., a company focused on creating protein capture arrays for sensitive, high-throughput, quantitative diagnostics. Mr. Brunel is also on the board of Anark Corporation and Xyleme, Inc.
AmideBio has a pipeline of novel biotherapeutics leveraging its knowhow to drive intelligent design of drug candidates targeting metabolic diseases. Its proprietary Cap-Clip™ technology delivers high-purity and difficult-to-manufacture BioPure™ peptides of any length with unprecedented purity for the pharmaceutical and biotech industry. AmideBio was founded in 2009 by Michael Stowell, Associate Professor of Molecular, Cellular and Developmental Biology at the University of Colorado, Boulder and Misha Plam, a serial entrepreneur.